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gesting that cells present in this compartment post-BMT may be
composed of both migrants and a resident population. To mediate
resistance to PC engraftment, effector CD8 cells must ﬁrst sur-
vive conditioning and the BMT milieu. B6BALB.B mice irradiated
at 3, 6, and 9 Gy were analyzed 24 hours later for CD8 H60-
speciﬁc T cells in the spleen and BM. Tertramer cells were
clearly identiﬁed in both compartments showing dose-dependent
increases. Importantly, 5 days after HCT with 1  107 H60
congenic (or BALB.B) TCD BM, PC rejection was evident, as
indicated by nondetectable splenic CFU activity in recipients of
these allogeneic, but not syngeneic TCD-BM. Notably, tetramer
cells were again detected in BM and spleen. Interestingly, their
frequency was 3fold higher in the marrow (mean, 6%) than in the
splenic compartment (mean, 1.7%) in sensitized recipients of ei-
ther syngeneic or MiHA allogeneic BM. These increases are con-
sistent with the predicted survival advantage of CD8 memory T
cells due to elevated bcl-2 levels. However, resistance did not occur
in syngeneic recipients due to lack of activation of H60-speciﬁc T
cells. These studies conclusively demonstrate that an antigen-
speciﬁc CD8 T-memory population responsible for resistance sur-
vives allogeneic BMT and is present in bone marrow and spleen
where resistance is presumed to occur. Studies are underway to
functionally and molecularly characterize this MiHA antigen-spe-
ciﬁc population during ongoing resistance post-HCT.
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IMMUNOLOGICAL AUTOLOGOUS STEM CELL GRAFT ENGINEERING US-
ING COMBINATION G-CSF AND ALDESLEUKIN (IL-2) IN PATIENTS
WITH NON-HODGKIN’S LYMPHOMA
Micallef, I.N.; Markovic, S.N.; Geyer, S.; Porrata, L.F.; Ansell, S.M.;
Inwards, D.J.; Gastineau, D.A.; Padley, D.J.; Armstrong, A.S.; Litzow,
M.R. Mayo Clinic College of Medicine, Rochester, MN.
Absolute lymphocyte count (ALC) recovery to  500/l by day
15 post-autologous peripheral blood stem cell transplant (APB-
SCT) is associated with an improved overall and event-free survival
(EFS) for patients with non-Hodgkin’s lymphoma (NHL). The
beneﬁt of the ALC post-APBSCT is likely due to natural killer
(NK) cells, because patients who achieved a normal NK cell count
( 80/l) on day 15 post-APBSCT (day 15 NK) had an improved
EFS compared with those whose day 15 NK was low. Finally, the
day 15 ALC correlates to the infused autograft absolute lympho-
cyte count (A-ALC) and not with total CD34 dose. Thus we
hypothesized that a peripheral blood stem cell mobilization regi-
men would be ideal if it could mobilize CD34 cells, lymphocytes,
and NK cells. A pilot study was undertaken using a sequential
mobilization regimen of granulocyte colony-stimulating factor (G-
CSF) followed by aldesleukin. Patients received G-CSF at 10
g/kg/day, and stem cell collections began on day 5 or later, when
the peripheral blood (PB) CD34 cell count was  10/l. Once
stem cell collection was complete and a minimum of 2 106 CD34
cells/kg were collected, patients received 1 subcutaneous injection
of aldesleukin and underwent 1 further apheresis the next day
collect lymphocytes. The dose levels of aldesleukin were 0, 0.5, 1,
1.5, and 2  106 U/m2. Patients then underwent conditioning for
APBSCT and on day 0 received all of the apheresis product,
including the extra collection of lymphocytes. PB lymphocyte
counts and subset analysis were measured at baseline (before G-
CSF), pre-aldesleukin, 1 day post-aldesleukin, and day 15 post
APBSCT. A total of 43 patients with NHL were entered in the
study. Of these, 26 completed an adequate CD34 collection, re-
ceived aldesleukin, and underwent an extra apheresis. The results
of these 26 patients are presented. The median CD34 collected,
A-ALC, autograft NK collected (A-NK), day 15 ALC, and day 15
NK for each dose level are given. The median times to neutrophil
and platelet engraftment were 13 and 12 days, respectively. We
conclude that aldesleukin up-regulates NK cell numbers. Dose
level 3 resulted in the best NK cell apheresis collection, the highest
PB NK cell count post-aldesleukin, on day 15 NK, and on day 15
ALC. Only at this dose did all patients achieve a normal day 15 NK
cell count. A phase II study is proposed using a sequential regimen
of G-CSF followed by aldesleukin at a dose of 1.5  106/m2 to
conﬁrm these results. Successful lymphocyte and NK cell engraft-
ment post-APBSCT may become as important as neutrophil and
platelet engraftment post-APBSCT.
Dose
Level
IL-2
Dose
#
Patients CD34
Total
A-ALC
Total
A-NK
Day 15
ALC
Day 15
NK
0 0 5 7.36  106/kg 0.57  109/kg 0.09  109/kg 744/l 194/l
1 0.5  106 IU/m2 5 4.37  106/kg 0.47  109/kg 0.09  109/kg 310/l 92/l
2 1  106 IU/m2 5 4.87  106/kg 0.67  109/kg 0.10  109/kg 700/l 120/l
3 1.5  106 IU/m2 5 6.96  106/kg 0.38  109/kg 0.11  109/kg 1380/l 472/l
4 2  106 IU/m2 6 3.73  106/kg 0.43  109/kg 0.10  109/kg 787/l 192/l
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INHIBITORY EFFECTS OF CYTOTOXICITY OF CYTOKINE ACTIVATED
AND EXPANDED HUMAN CD8 T CELLS BY A HUMAN NKG2D ALTER-
NATIVE SPLICE VARIANT
Karimi, M.A.; Cao, T.; Soares, L.; Negrini, R.S. Stanford University,
Stanford, CA.
NKG2D is an activating receptor that is expressed onCD8T cells
and & T cells where it up-regulates activation through T-cell
receptor (TCR) costimulation. NKG2D is triggered by ligands that
are structurally related to major histocompatibility complex (MHC)-1
and expressed by tissues early in ontogeny, stress, and transformation.
The function of NKG2D on natural killer (NK) cells and CD8 T
cells is mediated by 2 distinct pathways of signaling through its
association withDAP10 andDAP12. One functionally distinct human
NKG2D isoform has been identiﬁed. In evaluating human NKG2D
gene expression by reverse-transcription polymerase chain reaction
(RT-PCR) in CD8T cells derived from 7 different donors, we
consistently observed 2 distinct bands differing by 218bp. Cloning and
sequencing of both PCR amplicons revealed a previously described
alternatively spliced NKG2D variant from inclusion of intron 6.
Intron 6 inclusion introduces a stop codon, resulting in a truncated
protein product lacking the entire extracellular domain. To determine
the functional consequences of truncated NKG2D expression, we
isolated and cloned both full-length and truncatedNKG2D into pRJ3
vectors. Human CD8 T cells were tranduced and directed against
human cell line targets in Cr51 cytotoxicity assays. We found that
expression of the full-length NKG2D resulted in a15% increase in
cytotoxicity, whereas expression of the truncated NKG2D resulted in
70% reduction in cytotoxicity. Results were compared to CD8 T
cells transduced with an empty vector. To further elucidate the role of
each NKG2D isoform, we coexpressed full-length and truncated
NKG2D with DAP-10 or DAP-12. Coexpression of full-length
NKG2Dwith either DAP10 orDAP12 resulted in a comparable 25%
cytotoxicity versus NKG2D alone. Coexpression of full-length and
truncated NKG2D also resulted in reduction of up to 65% coexpres-
sion of the truncated NKG2D isoform with DAP10 or DAP12 did
not alter the reduction in cytotoxicity observed with truncated
NKG2D alone.We also performed experiments usingmurine CD8
T cells with human cell line targets. Overexpression of full-length
NKG2D resulted in a  32% increase in cytotoxicity, whereas coex-
pression of full-length NKG2D and DAP10 resulted in a 42% in-
crease in cytotoxicity. Collectively, these results demonstrate that the
NKG2D isform lacking the extracellular domain unexpectedly inhib-
its cytotoxicity in human CD8 T cells. Also of interest is whether
variability in expression of the truncated NKG2D isoform inﬂuences
the cytotoxic potency of activated CD8 T cells expanded from
different donors.
GVH/GVL
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RABBIT IGG LEVELS IN PATIENTS RECEIVING THYMOGLOBULIN AS
PART OF CONDITIONING BEFORE UNRELATED-DONOR ALLOGENEIC
STEM CELL TRANSPLANTATION
Remberger, M.; Sundberg, B. Karolinska Institutet, Clinical Immunol-
ogy, Karolinska University Hospital, Stockholm, Sweden.
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Purpose: Thymoglobulin (ATG) given before allogeneic hema-
topoietic stem cell transplantation (HSCT) with unrelated donors
reduces acute graft-versus-host disease (GVHD). However, the
possible role of serum concentration of rabbit ATG for the sub-
sequent development of acute GVHD after HSCT is unknown.
Methods: The serum concentration of rabbit IgG was analyzed by
enzyme-linked immunosorbent assasy in 61 patients after unre-
lated donor HSCT. Doses of ATG as part of the conditioning
ranged between 4 and 10 mg/kg. Stem cell source was bone
marrow (BM) in 28 cases and peripheral blood (PBSC) in 33.
Conditioning was mainly cyclophosphamide combined with total
body irradiation (TBI) or busulfan. Most patients received GVHD
prophylaxis with cyclosporine and methotrexate. Results: Even
though we found a good correlation between given ATG dose and
serum concentration of rabbit IgG after transplant (r 0.67), there
was a wide variation of rabbit IgG levels within each dose group.
After administration, levels of rabbit IgG decreased slowly and
could still be detected up to 5 weeks after HSCT. We found a
correlation between grade of acute GVHD and concentration of
rabbit IgG in serum obtained before transplantation (P  .017).
Patients with serum levels of rabbit IgG 70 mg/ml before HSCT
had very low risk for developing acute GVHD grades II-IV com-
pared with those with  70 mg/ml (11% vs 53%; P  .001).
Conclusion: Measuring rabbit IgG levels in patients receiving
ATG as prophylaxis against GVHD after HSCT may be a helpful
tool in decreasing the risk of severe GVHD.
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GENERATION OF TOLEROGENIC DENDRITIC CELLS AND REGULATORY
T CELLS THROUGH INTRAVENOUS DELIVERY OF AUTOLOGOUS PHO-
TOPHERESIS-INDUCED APOPTOTIC CELLS
Campbell, K.1; Huber, J.1; Rosenberg, A.1; Peters, C.1; Harriman, G.1;
Strobl, F.1; Peritt, D.1; Schwarz, A.2; Maeda, A.2; Schwarz, T.2 1.
Therakos, Inc., Exton, PA; 2. University Clinics Schleswig-Holstein,
Kiel, Germany.
Phagocytosis of apoptotic cells by macrophages or dendritic cells
has been shown to regulate immune responses both in vivo and in
vitro. Extracorporeal photopheresis (ECP) involves the clinical
reinfusion of peripheral blood leukocytes that are undergoing ap-
optosis following exposure ex vivo to 8-methoxypsoralen (8-MOP)
and UVA light. ECP is approved for the palliative treatment of
cutaneous T-cell lymphoma and has been reported to have utility
in immune-mediated inﬂammatory diseases, such as graft-versus-
host disease (GvHD) and solid-organ transplant rejection, and
autoimmune diseases, such as rheumatoid arthritis and Crohn’s
disease. We have evidence to suggest that ECP therapy may mod-
ulate host dendritic cell function and induce regulatory T-cell
generation. When coincubated with ECP-treated cells, activated
dendritic cells produce reduced levels of proinﬂammatory cyto-
kines, such as interleukin-12, whereas transforming growth fac-
tor- levels are modestly increased. Activation of CD4 T cells in
the presence of allogeneic dendritic cells and ECP-treated cells
promotes generation of a population of T cells that can suppress
proliferation of naive syngeneic T cells, as well as suppress inter-
feron- production. To conﬁrm these ﬁndings in vivo, we used a
murine contact hypersensitivity model. ECP-treated or control
leukocytes from mice sensitized with the hapten dinitroﬂuoroben-
zene (DNFB) were injected intravenously into naive recipients.
Compared with controls, mice that received ECP-treated cells
demonstrated signiﬁcantly less ear swelling after sensitization and
challenge with DNFB. Suppression of ear swelling was speciﬁc for
DNFB and was cell-mediated, as demonstrated by the ability to
transfer DNFB tolerance to naive mice, which could appropriately
respond to the unrelated hapten oxazalone. Transfer of this toler-
ance was abrogated by depletion of either CD4 or CD25T-cell
populations. Collectively, these results suggest that the delivery of
ECP-treated cells promotes generation of regulatory T cells that
are capable of modulating immune responses. Regulatory T cells
have been implicated in the control of GvHD, and as previously
reported, ECP has demonstrated beneﬁcial activity in GvHD. As a
result, international phase II clinical trials are currently underway
to assess the efﬁcacy of photopheresis in GvHD patients.
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PRETRANSPLANT RECIPIENT BLOOD CD14 PREDC LEVELS CORRE-
LATE WITH INCREASED ACUTE GVHD AFTER ALLOGENEIC PBSC
TRANSPLANTATION
Arpinati, M.1; Giannoullia, P.1; Chirumbolo, G.1; Bonifazi, F.1; Saun-
thararajah, Y.2; Bandini, G.1; Stanzani, M.1; Baccarani, M.1; Rondelli,
D.2 1. Research Center for Transplant Immunology, Institute of Hema-
tology, University of Bologna, Bologna, Italy; 2. Section of Hematology/
Oncology, University of Illinois at Chicago, Chicago, IL.
Host dendritic cells (DCs) present host alloantigens to donor T
lymphocytes. Human peripheral blood contains various circulating
DC precursors including CD11c myeloid preDC (mDC),
CD14 monocytic DC precursors (CD14 preDC) and plasma-
cytoid preDC (pDC). We used ﬂow cytometry to enumerate both
mDC (lin-, HLA-DR, and CD11c), mono-DC (CD14), and
pDC (lin-, HLA-DR, and CD123) numbers in the blood of
patients receiving an allogeneic HSCT. Fifty consecutive patients
undergoing HSCT from HLA-matched related (n  28) or unre-
lated (n  22) donors were enrolled in the study. The stem cell
source was bone marrow in all unrelated donors, and branulocyte
colony-stimulating factor (G-CSF) mobilized PBSC in related do-
nors. All patients received CsA and MTX as GVHD prophylaxis.
Moreover, 26 patients (52%) received ATG before transplant.
mDC and pDC PB counts were signiﬁcantly lower in patients than
in 28 age-matched healthy controls (8.8 cells/l [25th-75th per-
centile, 3.5–14.5] mDC, and 2.8 [1.3–5.5] pDC, versus 15.5 [12.1–
25.1] and 8.6 [5.6–13.1], respectively; P  .001). However the
mDC/pDC ratio was signiﬁcantly higher in the patient group (3.5
[1.6–6.2] vs 1.7 [1.3–2.6]; P  .002). CD14 preDC counts were
not signiﬁcantly different. Among the 46 patients who were evalu-
able, 12 (26%) developed acute GVHD grade II-IV. Risk factors
signiﬁcantly associated with acute GVHD were older age (P 
.01), PBSC transplantation (P  .02), and the absence of ATG in
the conditioning regimen (P  .01). Patients with acute GVHD
had signiﬁcantly higher pretransplantation mDC:pDC ratio (5.7
[3.3–16.4] vs 3.1 [1.6–5.5]; P  .03) and CD14 preDC counts
(395 [326–625] vs 284 [187–395]; P  .02). A subset analysis was
performed in PBSC patients, only 3 of whom had received ATG
before transplant. Among 26 evaluable patients, 10 (38%) devel-
oped acute GVHD grade II-IV. Besides older age (P  .02), the
only risk factors signiﬁcantly associated with acute GVHD in
PBSC patients were the pretransplantation mDC:pDC ratio (5.7
[4.1–13.1] vs 1.7 [1.2–2.9]; P  .008) and CD14 preDC counts
(395 [352–710] vs 259 [199–314]; P  .004). In multivariate anal-
ysis, only older age (P  .04) and pretransplantation circulating
CD14 preDC numbers (P  0.04) were signiﬁcantly associated
with acute GVHD in PBSC transplants. These ﬁndings demon-
strate that blood levels of DC precursors may correlate with a
higher risk of developing aGVHD. Future studies will be aimed at
depleting host preDC before allotransplant as a means of GVHD
prophylaxis.
26
ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) IN PA-
TIENTS UNDERGOING ALLOGENEIC BMT FOR THALASSAEMIA MAJOR
George, B.; Mathews, V.; Viswabandhya, A.; Kavitha, N.; Srivastava,
A.; Chandy, M. Department of Haematology, Christian Medical College,
Vellore, Tamilnadu, India.
Methods: Between October 1991 and June 2004, 152 thalasse-
mic patients who underwent allogeneic BMT and survived more
than 2 weeks were evaluated for graft-versus-host disease
(GVHD). Conditioning regimens included cusulfan (Bu) 16 mg/
kg, cyclophosphamide (Cy) 200 mg/kg, and antilymphocyte glob-
ulin (ALG) 120 mg/kg (in 91 patients); Bu 600 mg/m2 and Cy 200
mg/kg (in 51 patients), Bu 14 mg/kg, Cy 10 mg/kg, and ALG 120
mg/kg (in 8 patients), and others (in 2 patients). GVHD prophy-
laxis consisted of cyclosporine (CSA) alone in 11 patients, CSA and
methotrexate (MTx) (15 mg/m2 on day 1, 10 mg/m2 on days 3, 6,
and 11) in 40 patients and CSA and MTx (10 mg/m2 on day 1, 7
mg/m2 on days 3, 6, and 11) in 99 patients. All donors were 6
antigen HLA-matched sibling (91.4%) or family (8.6%) donors.
Results: There were 103 males and 49 females, with mean age of
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